Exhibit 99.1

FOR IMMEDIATE RELEASE

Emdeon Reports First Quarter 2011 Results

•

Revenue of $271.5 million, increased 14.4% over first quarter 2010

•

Non-GAAP Adjusted EBITDA of $68.8 million, increased 10.4% over first quarter 2010

•

Recent EquiClaim acquisition expands payment integrity solutions with leading healthcare audit and recovery services for commercial and government payers

NASHVILLE, Tenn. (May 5, 2011) – Emdeon Inc. (NYSE: EM), a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced financial results for the first quarter ended March 31, 2011, as summarized below:

										%
(In millions, except per share amts)		1Q 11				1Q 10				Change
Revenue		$	271.5			$	237.3				14.4	%
Net Income		$	7.3			$	4.3				70.7	%
Earnings per share (diluted)		$	0.05			$	0.02				150.0	%
Non-GAAP Adjusted EBITDA		$	68.8			$	62.4				10.4	%
Non-GAAP Adjusted EPS		$	0.23			$	0.21				9.5	%
Non-GAAP fully diluted shares			123.2				121.3				1.5	%

“We are pleased with our financial results for the first quarter. Across the board, our businesses performed according to plan and we continued to see solid growth in our revenue cycle management and payment services solutions,” said George Lazenby, Emdeon’s chief executive officer. “In addition, the market reception of our recently acquired revenue cycle management services, including Chamberlin Edmonds’ eligibility and enrollment solutions, has been positive and we are beginning to see success in cross-selling these services.”

Lazenby continued, “In addition, we recently announced the acquisition of EquiClaim, whose payment integrity solutions and strong management team are a welcome addition to Emdeon. This acquisition represents another important step in our strategic efforts to provide a comprehensive suite of payment integrity solutions to our customers.”

First quarter revenue was $271.5 million, an increase of 14.4%, compared to $237.3 million for the same period in 2010, as a result of recent acquisitions and organic growth. GAAP operating income for the first quarter of 2011 was $23.7 million compared to $30.8 million for the same period in 2010, a decrease of 23.3%, primarily due to higher depreciation and amortization expense related to 2010 acquisitions and capital expenditures. First quarter Non-GAAP Adjusted EBITDA grew 10.4% to $68.8 million, or 25.4% of revenue, from Non-GAAP Adjusted EBITDA of $62.4 million, or 26.3% of revenue, in the comparable period in 2010. The decrease in Non-GAAP Adjusted EBITDA as a percentage of revenue was primarily due to increased investment in new product and service initiatives combined with revenue mix changes, including the impact of recent acquisitions.

GAAP net income (before noncontrolling interest) for the first quarter of 2011 was $7.3 million compared to GAAP net income of $4.3 million for the same period in 2010. GAAP net income per diluted share for the first quarter of 2011 was $0.05 compared to $0.02 for the same period in 2010. Non-GAAP Adjusted Net Income per fully diluted share for the first quarter of 2011 was $0.23, using a weighted average fully diluted share count of 123.2 million, compared to $0.21, using a weighted average fully diluted share count of 121.3 million, for the same period in 2010.

A reconciliation of Emdeon’s financial results determined in accordance with U.S. Generally Accepted Accounting Principles (GAAP) to certain non-GAAP financial measures has been provided in the financial statement tables included in this release to supplement its unaudited condensed consolidated financial statements presented on a GAAP basis. An explanation of these non-GAAP measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”

Financial Outlook

Emdeon maintained its previously announced 2011 annual financial outlook ranges of $1.105 to $1.135 billion for revenue, $300 to $310 million for Non-GAAP Adjusted EBITDA and $1.00 to $1.06 for Non-GAAP Adjusted Net Income per fully diluted share (using a weighted average share count of 124.0 million).

Notice of Conference Call and Webcast

Emdeon will conduct a conference call/webcast for investors and institutional analysts on Thursday, May 5, 2011 at 5:00 pm Eastern Time/4:00 pm Central Time to discuss Emdeon’s financial results.

To access Emdeon’s live conference call and webcast, dial 866-831-6224 (617-213-8853 for international calls) using conference code 66554525 or visit the Investors section of Emdeon’s website: www.emdeon.com. Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software to access the webcast. For those unable to listen to the live broadcast, a conference call replay will be available for one week following the conference call by calling 888-286-8010 (617-801-6888 for international calls) using conference code 67368789. A webcast replay will also be archived on Emdeon’s website for at least 30 days following the conference call.

About Emdeon

Emdeon is a leading provider of revenue and payment cycle management and clinical information exchange solutions, connecting payers, providers and patients in the U.S. healthcare system. Emdeon’s product and service offerings integrate and automate key business and administrative functions of its payer and provider customers throughout the patient encounter. Through the use of Emdeon’s comprehensive suite of products and services, which are designed to easily integrate with existing technology infrastructures, customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle and clinical information exchange processes. For more information, visit www.emdeon.com.

Forward-Looking Statements

Statements made in this press release that express Emdeon’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements, which Emdeon intends to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements often include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. Forward-looking statements may include information concerning Emdeon’s possible or assumed future results of operations, including descriptions of Emdeon’s revenues, profitability, outlook and overall business strategy. You should not place undue reliance on these statements because they are subject to numerous uncertainties and factors relating to Emdeon’s operations and business environment, all of which are difficult to predict and many of which are beyond Emdeon’s control. Although Emdeon believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect Emdeon’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements, including but not limited to: effects of competition, including competition from entities that are customers for certain of Emdeon’s products and services; Emdeon’s ability to maintain relationships with its customers and channel partners; Emdeon’s ability to effectively cross-sell its products and services to existing customers and to continue to generate revenue and maintain profitability by developing or acquiring and successfully deploying new or updated products and services; pricing pressures on Emdeon’s products and services; the anticipated benefits from acquisitions not being fully realized or not being realized within the expected time frames; and general economic, business or regulatory conditions affecting the healthcare information technology and services industries; as well as the other risks discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections and elsewhere in Emdeon’s Annual Report on Form 10-K for the year ended December 31, 2010, as well as Emdeon’s periodic and other reports, filed with the Securities and Exchange Commission.

You should keep in mind that any forward-looking statement made by Emdeon herein, or elsewhere, speaks only as of the date on which made. Emdeon expressly disclaims any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in Emdeon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

# # #

Contacts:

Investor Relations

Tommy Lewis
615.932.3235
tlewis@emdeon.com

Emdeon Inc.
Condensed Consolidated Statements of Operations
(unaudited and amounts in thousands, except share and per share amounts)

		For the Three Months
		Ended March 31,
		2011				2010
Revenue		$	271,499			$	237,279
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)			169,254				143,986
Development and engineering			8,904				8,554
Sales, marketing, general and administrative			31,647				26,119
Depreciation and amortization			38,022				27,775
Operating income			23,672				30,845
Interest income			(3	)			(3	)
Interest expense			12,629				15,665
Other			(1,403	)			290
Income before income tax provision			12,449				14,893
Income tax provision			5,174				10,630
Net income			7,275				4,263
Net income attributable to noncontrolling interest			2,881				2,374
Net income attributable to Emdeon Inc.		$	4,394			$	1,889
Net income per share Class A common stock:
Basic		$	0.05			$	0.02
Diluted		$	0.05			$	0.02
Weighted average common shares outstanding:
Basic			90,987,352				90,461,968
Diluted			91,246,531				90,468,057

Emdeon Inc.
Condensed Consolidated Balance Sheets
(unaudited and amounts in thousands, except share amounts)

		March 31,				December 31,
		2011				2010
Assets
Current assets:
Cash and cash equivalents		$	135,084			$	99,188
Accounts receivable, net of allowance for doubtful accounts of $ 5,756 and $5,394 at March 31, 2011 and December 31, 2010, respectively			175,709				174,191
Deferred income tax assets			7,171				7,913
Prepaid expenses and other current assets			25,895				25,020
Total current assets			343,859				306,312
Property and equipment, net			229,879				231,307
Goodwill			908,008				908,310
Intangible assets, net			1,013,053				1,035,886
Other assets, net			9,298				9,750
Total assets		$	2,504,097			$	2,491,565
Liabilities and equity
Current liabilities:
Accounts payable		$	8,232			$	4,732
Accrued expenses			111,239				112,245
Deferred revenues			13,161				12,130
Current portion of long-term debt			12,493				12,494
Total current liabilities			145,125				141,601
Long-term debt, excluding current portion			934,969				933,749
Deferred income tax liabilities			199,595				200,357
Tax receivable agreement obligations to related parties			137,964				138,533
Other long-term liabilities			17,514				22,037
Commitments and contingencies
Equity:
Preferred stock (par value, $0.00001), 25,000,000 shares authorized and 0 shares issued and outstanding			—				—
Class A common stock (par value, $0.00001), 400,000,000 shares authorized and 91,127,779 and 91,064,486 shares outstanding at March 31, 2011 and December 31, 2010, respectively			1				1
Class B common stock, exchangeable (par value, $0.00001), 52,000,000 shares authorized and 24,689,142 shares outstanding at March 31, 2011 and December 31, 2010			—				—
Additional paid-in capital			743,458				738,888
Contingent consideration			1,955				1,955
Accumulated other comprehensive loss			(1,937	)			(2,569	)
Retained earnings			57,644				53,250
Emdeon Inc. equity			801,121				791,525
Noncontrolling interest			267,809				263,763
Total equity			1,068,930				1,055,288
Total liabilities and equity		$	2,504,097			$	2,491,565

Emdeon Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited and amounts in thousands)

		For the Three Months
		Ended March 31,
		2011				2010
Operating activities
Net income		$	7,275			$	4,263
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			38,022				27,775
Equity compensation expense			5,573				3,675
Deferred income tax expense			—				4,666
Amortization of debt discount and issuance costs			3,455				3,135
Amortization of discontinued cash flow hedge from other comprehensive loss			922				1,453
Change in contingent consideration			(1,403	)			290
Change in fair value of interest rate swap (not subject to hedge accounting)			(2,556	)			—
Other			5				281
Changes in operating assets and liabilities:
Accounts receivable			(1,519	)			3,347
Prepaid expenses and other			1,209				1,646
Accounts payable			4,766				(2,434	)
Accrued expenses and other liabilities			5,104				3,173
Deferred revenues			1,031				14
Tax receivable agreement obligations to related parties			(2,913	)			(1,480	)
Net cash provided by operating activities			58,971				49,804
Investing activities
Purchases of property and equipment			(19,654	)			(12,949	)
Payments for acquisitions, net of cash acquired			—				(26,444	)
Net cash used in investing activities			(19,654	)			(39,393	)
Financing activities
Debt principal payments			(2,138	)			(1,888	)
Other			(1,283	)			(104	)
Net cash used in financing activities			(3,421	)			(1,992	)
Net increase in cash and cash equivalents			35,896				8,419
Cash and cash equivalents at beginning of period			99,188				211,999
Cash and cash equivalents at end of period		$	135,084			$	220,418

Segment Information
(unaudited and amounts in thousands)

		For the Three Months Ended March 31, 2011
														Corporate &
		Payer				Provider				Pharmacy				Eliminations				Consolidated
Revenue from external customers
Claims management		$	47,554			$	—			$	—			$	—			$	47,554
Payment services			62,236				—				—				—				62,236
Patient statements			—				63,517				—				—				63,517
Revenue cycle management			—				69,854				—				—				69,854
Dental			—				7,733				—				—				7,733
Pharmacy services			—				—				20,605				—				20,605
Inter-segment revenue			856				116								(972	)			—
Net revenue			110,646				141,220				20,605				(972	)			271,499
Costs and expenses:
Cost of operations			75,328				86,170				8,663				(907	)			169,254
Development and engineering			2,858				4,320				1,726				—				8,904
Sales, marketing, general and administrative			6,813				10,516				1,301				13,017				31,647
Segment contribution (1)		$	25,647			$	40,214			$	8,915			$	(13,082	)			61,694
Depreciation and amortization																			38,022
Interest income																			(3	)
Interest expense																			12,629
Other																			(1,403	)
Income before income tax provision																		$	12,449

		For the Three Months Ended March 31, 2010
														Corporate &
		Payer				Provider				Pharmacy				Eliminations				Consolidated
Revenue from external customers
Claims management		$	45,148			$	—			$	—			$	—			$	45,148
Payment services			56,820				—				—				—				56,820
Patient statements			—				66,589				—				—				66,589
Revenue cycle management			—				41,089				—				—				41,089
Dental			—				7,937				—				—				7,937
Pharmacy services			—				—				19,696				—				19,696
Inter-segment revenue			873				87				—				(960	)			—
Net revenue			102,841				115,702				19,696				(960	)			237,279
Costs and expenses:
Cost of operations			66,631				71,558				6,725				(928	)			143,986
Development and engineering			2,975				3,864				1,715				—				8,554
Sales, marketing, general and administrative			6,959				6,890				1,558				10,712				26,119
Segment contribution (1)		$	26,276			$	33,390			$	9,698			$	(10,744	)			58,620
Depreciation and amortization																			27,775
Interest income																			(3	)
Interest expense																			15,665
Other																			290
Income before income tax provision																		$	14,893

Explanation of Non-GAAP Financial Measures

Emdeon’s management believes that, in order to properly understand Emdeon’s short-term and long-term financial trends, investors may wish to consider the impact of certain non-cash or non-operating items, when used as a supplement to financial performance measures prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). These items result from facts and circumstances that vary in frequency and/or impact continuing operations. In addition, management uses results of operations before such excluded items to evaluate the operational performance of Emdeon as a basis for strategic planning and, in the case of Adjusted EBITDA, as a performance evaluation metric in determining achievement of certain executive and management incentive compensation programs. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition to the description provided below, reconciliations of GAAP to non-GAAP results are provided in the financial statement tables included in this release.

In this release, Emdeon defines Adjusted EBITDA as EBITDA (which is defined as net income before income tax provision (benefit), net interest expense and depreciation and amortization), plus certain other non-cash or non-operating items (collectively, “EBITDA Adjustments”).

In this release, Emdeon defines Adjusted Net Income as the sum of (i) GAAP net income, (ii) EBITDA Adjustments, (iii) non-cash interest expense and (iv) depreciation and amortization expense resulting from adjustments of assets to fair value in connection with acquisition accounting, less income taxes computed based on a normalized income tax rate. Emdeon defines Adjusted Net Income per fully diluted share as the quotient of Adjusted Net Income and weighted average shares outstanding, assuming all potentially dilutive securities (except for contingently issuable shares subject to performance conditions and shares or other potentially dilutive securities not otherwise contemplated in the share denominator utilized in the applicable year’s financial outlook range) are fully dilutive and outstanding shares from their date of grant or issuance.

To properly evaluate Emdeon’s business, Emdeon encourages investors to review the GAAP financial information included in this release, and not rely on any single financial measure to evaluate Emdeon’s business. Emdeon also strongly encourages investors to review the reconciliation of GAAP net income and GAAP net income per diluted share to the applicable non-GAAP measures of Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income per fully diluted share. These non-GAAP measures, as Emdeon defines them, may not be similar to non-GAAP measures used by other companies.

Management uses Adjusted EBITDA and Adjusted Net Income per fully diluted share to facilitate a comparison of Emdeon’s operating performance on a consistent basis from period to period that, when viewed in combination with Emdeon’s GAAP results, management believes provides a more complete understanding of factors and trends affecting Emdeon’s business than GAAP measures alone. Management believes these non-GAAP measures assist Emdeon’s board of directors, management, lenders and investors in comparing Emdeon’s operating performance on a consistent basis because they remove where applicable, the impact of Emdeon’s capital structure, asset base, acquisition accounting, non-cash charges and non-operating items from Emdeon’s operations.

Emdeon also presents Adjusted EBITDA and Adjusted Net Income per fully diluted share on a forward-looking basis as part of its Financial Outlook for 2011. Emdeon is unable to present a quantitative

reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because management cannot predict, with sufficient reliability, contingent payments relating to past and possible future acquisitions, changes in the fair value of Emdeon’s interest rate swap agreement and the effect on income taxes of these and other items attributable to Emdeon’s capital structure, all of which are difficult to estimate and primarily dependent on future events.

Emdeon Inc.
Reconciliation of GAAP Net Income to Adjusted EBITDA
(unaudited and amounts in thousands)

		For the Three Months
		Ended March 31,
		2011				2010
Net income		$	7,275			$	4,263
Interest expense, net			12,626				15,662
Income tax provision			5,174				10,630
Depreciation and amortization			38,022				27,775
EBITDA			63,097				58,330
Equity-based compensation			5,573				3,675
Acquisition method adjustments			—				176
Facilities consolidation costs			96				430
Acquisition-related costs			1,237				939
Tax receivable agreements change in estimate			226				(1,480	)
Contingent consideration adjustments			(1,403	)			290
EBITDA Adjustments			5,729				4,030
Adjusted EBITDA		$	68,826			$	62,360

Emdeon Inc.
Reconciliation of GAAP Net Income to Adjusted Net Income
(unaudited and amounts in thousands)

		For the Three Months
		Ended March 31,
		2011				2010
Net income		$	7,275			$	4,263
Income tax provision			5,174				10,630
EBITDA Adjustments			5,729				4,030
Non-cash interest expense			2,569				4,588
Depreciation and amortization resulting from acquisition method adjustments			26,086				19,176
Adjusted net income before income taxes			46,833				42,687
Normalized income tax provision			18,499				16,861
Adjusted Net Income		$	28,334			$	25,826

Emdeon Inc.
Reconciliation of GAAP Net Income Per Diluted Share of Class A Common Stock to
Adjusted Net Income Per Fully Diluted Share⁽¹⁾
(unaudited)

		For the Three Months
		Ended March 31,
		2011				2010
Net income per diluted share of Class A common stock		$	0.05			$	0.02
Impact of assuming full dilution of all outstanding equity instruments for the period			0.01				0.01
Adjustments on a per share basis:
Income tax provision			0.04				0.09
EBITDA Adjustments			0.05				0.03
Non-cash interest expense			0.02				0.04
Depreciation and amortization resulting from acquisition method adjustments			0.21				0.16
Adjusted net income before income taxes			0.38				0.35
Normalized income tax provision			0.15				0.14
Adjusted Net Income per fully diluted share			0.23			$	0.21

		(shares in thousands)
		For the Three Months
		Ended March 31,
Weighted average of:		2011				2010
Class A shares outstanding			90,987				90,462
Class B shares outstanding			24,482				24,725
Restricted stock units outstanding			792				572
Options to purchase Class A shares outstanding			6,907				5,536
Shares assumed in Adjusted Net Income per fully diluted share calculation			123,168				121,295